Paper Details

  1. Home
  2. Paper Details

High remission and low relapse with prolonged intensive DMARD therapy in rheumatoid arthritis (PRINT): A multicenter randomized clinical trial.

Author: ChenLi-Na, DengXue-Rong, FangYong-Fei, GuFei, HaoYan-Jie, HeJing, KeystoneEdward, LiRu, LiXing-Fu, LiZhan-Guo, LiuHua-Xiang, LiuXiang-Yuan, LiuYi, McInnesIain B, SuYin, SunLing-Yun, XueYu, ZhangZhuo-Li, ZhaoCheng, ZhaoJin-Xia, ZhaoYi, ZhouWei, ZhuPing, ZouHe-Jian, ZouQing-Hua

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Intensive treatment with disease-modifying antirheumatic drugs can help patients with rheumatoid arthritis achieve remission. Patients who achieve remission have lower relapse rates. Leflunomide is a good option for maintenance treatment.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: To determine whether prolonged intensive disease-modifying antirheumatic drug (DMARD) treatment (PRINT) leads to high remission and low relapse rates in patients with severe rheumatoid arthritis (RA). METHODS: In this multicenter, randomized and parallel treatment trial, 346 patients wi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4956780/

データ提供：米国国立医学図書館（NLM）

Prolonged Intensive DMARD Therapy in Rheumatoid Arthritis

The study delves into a significant challenge in the management of rheumatoid arthritis (RA), investigating the impact of prolonged intensive disease-modifying antirheumatic drug (DMARD) therapy on remission rates and relapse rates. Researchers conducted a multicenter randomized clinical trial, comparing different DMARD treatment regimens and their long-term effects on RA patients. The study found that prolonged intensive DMARD therapy led to high remission rates and low relapse rates, highlighting the potential benefits of this treatment approach.

Finding Relief: A New Approach to Rheumatoid Arthritis Treatment

The study suggests that prolonged intensive DMARD therapy could be a game-changer in the treatment of rheumatoid arthritis. The results indicate a significant improvement in remission rates and a reduction in relapses, offering a more effective and long-lasting solution for managing this chronic condition. It's like discovering a hidden oasis of relief in a desert of treatment options, offering a more sustainable and hopeful approach to managing rheumatoid arthritis.

Managing Rheumatoid Arthritis: Exploring Long-Term Therapies

This research underscores the importance of exploring long-term treatment strategies for rheumatoid arthritis. The study's findings suggest that prolonged intensive DMARD therapy could be a valuable tool for achieving and maintaining remission, leading to a better quality of life for patients. It's like navigating a vast desert of treatment options, seeking a solution that provides long-lasting relief and a more hopeful future for those living with rheumatoid arthritis.

Dr.Camel's Conclusion

This study provides valuable insights into the potential of prolonged intensive DMARD therapy for managing rheumatoid arthritis. The findings suggest that this approach could lead to higher remission rates and lower relapse rates, offering a more effective and sustainable treatment option for individuals living with this chronic condition. It's a step towards a more hopeful future for those seeking lasting relief from the challenges of rheumatoid arthritis.

Date :
  1. Date Completed 2017-02-07
  2. Date Revised 2021-01-09
Further Info :

Pubmed ID

27428186

DOI: Digital Object Identifier

PMC4956780

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.